SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rohit Nanavati who wrote (165)5/8/1997 10:52:00 AM
From: Techperson   of 998
 
Bloomberg News, 9:39 AM EDT - Cephalon and FDA officials offered an agency advisory panel conflicting views of studies of Cephalon's Lou Gehrig's disease drug. While CEPH and CHIR officials said the drug can help slow the devastating effects of the disease, FDA officials said contradictory studies of the drug have left them unconvinced.
"Our view is the fact that 1202 (European study) does not corroborate the findings of 1200 (U.S. study) is very disconcerting," said Paul Leber, Director of the FDA's division of neuropharmacological drugs.
Later today the panel will be asked a series of questions, one of which is if it can "on the strength of the evidence provided in this single study (the U.S. study) and taking into account the failure of the only other completed adequate and well-controlled clinical investigation to confirm its findings, conclude that there is substantial evidence that Myotrophin is effective."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News